Venetoclax in Combination With Ublituximab and Umbralisib (TGR-1202) in Patients With Relapsed or Refractory CLL/SLL



Status:Recruiting
Conditions:Blood Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:10/11/2018
Start Date:April 9, 2018
End Date:December 2021
Contact:TG Therapeutics Clinical Support Team
Email:clinicalsupport@tgtxinc.com
Phone:212-554-4484

Use our guide to learn which trials are right for you!

This study will be a standard 3+3 design with a lead in of umbralisib (TGR-1202) +
ublituximab for 12 weeks, i.e. 3 cycles, followed by venetoclax (20 mg - 200 mg) along with
umbralisib (TGR-1202) and ublituximab for patients with relapsed/refractory CLL.


Inclusion Criteria:

- Confirmed diagnosis of B-cell Chronic Lymphocytic Leukemia

- Refractory to or relapsed after at least 1 prior treatment regimen

- Eastern Cooperative Oncology Group (ECOG) score of 0 to 2

Exclusion Criteria:

- Any major surgery, chemotherapy or immunotherapy within the last 21 days

- Known hepatitis B virus, hepatitis C virus or HIV infection

- Known histological transformation from CLL to an aggressive lymphoma (Richter's)
We found this trial at
2
sites
2010 E 90th St
Cleveland, Ohio 44195
(866) 223-8100
Cleveland Clinic Taussig Cancer Center At Taussig Cancer Institute, more than 250 highly skilled doctors,...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
601 Elmwood Avenue
Rochester, New York 14642
?
mi
from
Rochester, NY
Click here to add this to my saved trials